1. Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study. Issue 4 (20th April 2022) Authors: Tannir, Nizar M; Cho, Daniel C; Diab, Adi; Sznol, Mario; Bilen, Mehmet A; Balar, Arjun V; Grignani, Giovanni; Puente, Erika; Tang, Lily; Chien, David; Hoch, Ute; Choudhury, Arkopal; Yu, Danni; Currie, Sue L; Tagliaferri, Mary A; Zalevsky, Jonathan; Siefker-Radtke, Arlene O; Hurwitz, Michael E Journal: Journal for immunotherapy of cancer Issue: Volume 10:Issue 4(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗